Opinion

Video

Treatment Considerations for Patients With HER2+ NSCLC

Key Takeaways

  • Clinicians must balance therapeutic benefits and risks, particularly concerning adverse events like interstitial lung disease, by tailoring treatment plans to individual patient needs.
  • Evolving strategies to address resistance to HER2-directed therapies focus on understanding resistance mechanisms and developing novel agents or combination therapies.
SHOW MORE

Panelists discuss how clinicians carefully weigh the efficacy of HER2-directed therapies against their safety profiles, particularly focusing on managing serious adverse events like interstitial lung disease, while also considering emerging strategies to combat resistance to these treatments as research in the field progresses.

Related Videos
5 experts are featured in this series
5 experts are featured in this series
Christine Funke, MD
1 expert in this video
1 expert in this video
Dr Mingyang Song
Casey Koch, PharmD, sitting for a video interview
1 expert in this video
1 expert in this video
Dr John Heymach
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo